Investing.com - Financial Markets Worldwide

BioDlink International Co Ltd (1875)

Hong Kong
Currency in HKD
2.41
-0.09(-3.60%)
Closed·
1875 Scorecard
Full Analysis
Net income is expected to grow this year
1875 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
2.352.43
52 wk Range
1.482.94
Key Statistics
Edit
Bid/Ask
2.38 / 2.44
Prev. Close
2.41
Open
2.41
Day's Range
2.35-2.43
52 wk Range
1.48-2.94
Volume
169.6K
Average Volume (3m)
249.4K
1-Year Change
32.98%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1875 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 12
Trading at a low P/E ratio relative to near-term earnings growth
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

BioDlink International Co Ltd Company Profile

BioDlink International Company Limited, an investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat advanced, metastatic or recurrent non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule for the treatment of newly diagnosed glioblastoma multiforme or anaplastic astrocytoma that recurs or progresses after conventional treatment. In addition, the company develops TAB014 that has completed Phase III clinical trial for the treatment of wet age-related macular degeneration (wAMD); TAE020, which is in preclinical trial to treat acute myeloid leukemia; and TAC020, which is in preclinical trial for the treatment of various solid tumors. Further, it is involved in contract development and manufacturing organization (CDMO)/contract manufacture organization (CMO) business; and license-out of self-developed biological drugs. The company was formerly known as TOT BIOPHARM International Company Limited and changed its name to BioDlink International Company Limited in July 2025. BioDlink International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
611
Market
Hong Kong

Compare 1875 to Peers and Sector

Metrics to compare
1875
Peers
Sector
Relationship
P/E Ratio
50.9x−16.1x−0.5x
PEG Ratio
0.250.280.00
Price/Book
2.4x6.3x2.6x
Price / LTM Sales
1.6x23.6x3.3x
Upside (Analyst Target)
2.3%−0.6%43.5%
Fair Value Upside
Unlock−10.6%6.9%Unlock

Earnings

Latest Release
Apr 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
577.73M / --
EPS Revisions
a
a
Unlock
Last 90 days

1875 Income Statement

FAQ

What Stock Exchange Does BioDlink International Trade On?

BioDlink International is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for BioDlink International?

The stock symbol for BioDlink International is "1875."

What Is the BioDlink International Market Cap?

As of today, BioDlink International market cap is 1.93B.

What Is BioDlink International's Earnings Per Share (TTM)?

The BioDlink International EPS (TTM) is 0.05.

From a Technical Analysis Perspective, Is 1875 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has BioDlink International Stock Split?

BioDlink International has split 0 times.

How Many Employees Does BioDlink International Have?

BioDlink International has 611 employees.

What is the current trading status of BioDlink International (1875)?

As of 07 Aug 2025, BioDlink International (1875) is trading at a price of 2.41, with a previous close of 2.41. The stock has fluctuated within a day range of 2.35 to 2.43, while its 52-week range spans from 1.48 to 2.94.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.